Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Centessa Pharmaceuticals Plc ADR
(NQ:
CNTA
)
8.270
-0.080 (-0.96%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Centessa Pharmaceuticals Plc ADR
< Previous
1
2
3
4
5
Next >
Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 12, 2023
Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market.
Via
Benzinga
InMode, Daktronics, Domino's Pizza And Other Big Stocks Moving Higher On Wednesday
July 12, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Centessa Pharmaceuticals: Q1 Earnings Insights
May 12, 2023
Via
Benzinga
NASDAQ: CNTA Investor Alert: Deadline on November 28, 2022 in Lawsuit against Centessa Pharmaceuticals plc
November 28, 2022
San Diego, CA -- (SBWIRE) -- 11/28/2022 --
Via
SBWire
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors
July 10, 2023
Enrollment progressing toward interim analysis planned when 36 subjects reach 12 weeks on treatment in Part 1 of study
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Pancreatic Cancer Trials & New Treatments Receiving Increased Funding as Incidences of Cancer Grows
June 23, 2023
Pancreatic Cancer Trials & New Treatments Receiving Increased Funding as Incidences of Cancer Grows
Via
News Direct
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2023
June 21, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 12, 2023
June 12, 2023
Via
Benzinga
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
May 24, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B
May 22, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
May 12, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022
March 30, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
March 27, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines
March 01, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
March 17, 2023
Via
Benzinga
Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Long Term Shareholder Notice: Investigation of Potential Wrongdoing
February 14, 2023
San Diego, CA -- (SBWIRE) -- 02/14/2023 -- An investigation was announced for investors in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) concerning potential breaches of fiduciary duties by...
Via
SBWire
Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
February 06, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference
February 02, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
January 26, 2023
LB101 is a conditionally tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody being developed for solid tumors
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
December 10, 2022
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson
November 30, 2022
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Reminds Centessa Pharmaceuticals plc (CNTA) Investors of Class Action Deadline and Encourages Investors to Actively Participate
November 28, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
November 27, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
CENTESSA PHARMACEUTICALS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess Of $100,000 of Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTA
November 25, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
CENTESSA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Centessa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
November 25, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Best Buy, Abercrombie & Fitch, Burlington Stores And Some Other Big Stocks Moving Higher On Tuesday
November 22, 2022
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
November 21, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
November 16, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm
November 11, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
November 10, 2022
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.